** Nyrada NYR.AX soars 9.2% to A$0.083, highest since Jan. 23; set for biggest intraday pct gain since Dec. 16, 2024
** Biotechnology co gets Human Research Ethics Committee's (HREC) approval to start its first-in-human Phase Ia clinical trial for its lead drug candidate NYR-BI03
** NYR-BI03 is used to treat stroke, traumatic brain injury
** Stock down 8.5% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。